CytomX Therapeutics, Inc.
CTMX
$2.98
$0.041.36%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -242.16% | -154.50% | 102.59% | 332.83% | 151.64% |
| Total Depreciation and Amortization | -26.33% | -22.17% | -30.53% | -16.98% | -17.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.50% | 37.18% | 59.91% | 120.82% | 97.94% |
| Change in Net Operating Assets | 74.64% | 45.75% | -0.85% | -32.15% | -16.25% |
| Cash from Operations | 1.40% | 12.34% | 18.16% | 9.75% | 11.16% |
| Capital Expenditure | 67.83% | 29.03% | 80.04% | 49.59% | 65.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -430.14% | -159.52% | -130.73% | -133.19% | 105.28% |
| Cash from Investing | -431.48% | -159.92% | -130.99% | -134.30% | 109.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,514.56% | 1,368.31% | 1,641.02% | 1,636.43% | 899.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,594.24% | 1,368.31% | 1,641.02% | 172.26% | -75.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -258.52% | -218.55% | -143.58% | 141.33% | 157.16% |